<DOC>
	<DOCNO>NCT00909597</DOCNO>
	<brief_summary>This double-blind , double-dummy 3 arm study evaluate efficacy , safety tolerability taspoglutide versus pioglitazone patient type 2 diabetes mellitus inadequately control sulfonylurea monotherapy sulfonylurea plus metformin combination therapy . After initial screening period , patient randomize one 3 group , receive ) taspoglutide 10mg sc weekly , b ) taspoglutide 20mg sc weekly 4 week taspoglutide 10mg sc weekly c ) pioglitazone 45mg/day po 4 week pioglitazone 30mg/day po.The anticipated time study treatment 24 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Pioglitazone Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes mellitus ; treat stable sulfonylurea monotherapy metformin + sulfonylurea &gt; =12 week prior screen ; HbA1c &gt; =7.0 % &lt; =10 % screening ; stable weight +/5 % &gt; =12 week prior screen . type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes ; clinically significant diabetic complication ; clinically symptomatic gastrointestinal disease ; &gt; 3 episode severe hypoglycemia within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>